Jove
Visualize
Contáctanos
JoVE
x logofacebook logolinkedin logoyoutube logo
ACERCA DE JoVE
Visión GeneralLiderazgoBlogCentro de Ayuda JoVE
AUTORES
Proceso de PublicaciónConsejo EditorialAlcance y PolíticasRevisión por ParesPreguntas FrecuentesEnviar
BIBLIOTECARIOS
TestimoniosSuscripcionesAccesoRecursosConsejo Asesor de BibliotecasPreguntas Frecuentes
INVESTIGACIÓN
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchivo
EDUCACIÓN
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualCentro de Recursos para ProfesoresSitio de Profesores
Términos y Condiciones de Uso
Política de Privacidad
Políticas

Videos de Conceptos Relacionados

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

159
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
159
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

2.6K
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
2.6K
Pulmonary Hypertension: Classification and Pathogenesis01:30

Pulmonary Hypertension: Classification and Pathogenesis

173
Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
173
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

148
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
148
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

8.8K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
8.8K
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

169
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
169

También podría leer

Artículos Relacionados

Artículos vinculados a este trabajo por autores compartidos, revista y gráfico de citas.

Ordenar por
Same author

Immune regulatory mechanisms in the tumor microenvironment and their applications in cancer therapy: from basic research to clinical translation.

Frontiers in immunology·2026
Same author

Sex differences in the renal T cell profile in DOCA-salt hypertension are independent of MR activation and increases in blood pressure.

American journal of physiology. Renal physiology·2026
Same author

Development and External Validation of a Machine Learning-Based Risk Classification Score for Prostate Cancer-Specific Cardiovascular Risk.

JCO oncology practice·2026
Same author

Purine metabolic adaptation protects the endothelium from disturbed flow-induced DNA damage and atherosclerosis.

Proceedings of the National Academy of Sciences of the United States of America·2026
Same author

Histone Deacetylase 9 Gene Deletion Ameliorates Aging-Related Adipose Tissue Senescence and Mitochondrial Dysfunction in Mice.

Aging cell·2026
Same author

PFKFB3 activates CAD to enhance de novo pyrimidine synthesis for cell growth.

Cell reports·2026

Video Experimental Relacionado

Updated: Jun 27, 2025

A Model of Reverse Vascular Remodeling in Pulmonary Hypertension Due to Left Heart Disease by Aortic Debanding in Rats
07:41

A Model of Reverse Vascular Remodeling in Pulmonary Hypertension Due to Left Heart Disease by Aortic Debanding in Rats

Published on: March 1, 2022

2.9K

Kinasa de unión a PDZ, un nuevo regulador de la remodelación vascular en la hipertensión arterial pulmonar

Zsuzsanna Bordan1, Robert K Batori1, Stephen Haigh1

  • 1Vascular Biology Center (Z.B., R.K.B., S.H., Z.L.B., M.A.W., Q.M., Y.H., N.L.W., D.W.S., D.J.R.F.), Medical College of Georgia, Augusta University.

Circulation
|April 29, 2024
PubMed
Resumen
Este resumen es generado por máquina.

La quinasa de unión a PDZ (PBK) es un nuevo objetivo para la hipertensión arterial pulmonar (HAP). La upregulación de PBK en las arterias pulmonares impulsa la proliferación celular y la progresión de la enfermedad, lo que sugiere que los inhibidores de PBK podrían tratar la HAP.

Palabras clave:
Proliferación de las célulasCitoquinesis y sus efectoshipertensión pulmonarLas ratascélulas del músculo lisoremodelación vascular

Más Videos Relacionados

Right Ventricular Systolic Pressure Measurements in Combination with Harvest of Lung and Immune Tissue Samples in Mice
10:20

Right Ventricular Systolic Pressure Measurements in Combination with Harvest of Lung and Immune Tissue Samples in Mice

Published on: January 16, 2013

25.3K
Hemodynamic Characterization of Rodent Models of Pulmonary Arterial Hypertension
09:40

Hemodynamic Characterization of Rodent Models of Pulmonary Arterial Hypertension

Published on: April 11, 2016

21.0K

Videos de Experimentos Relacionados

Last Updated: Jun 27, 2025

A Model of Reverse Vascular Remodeling in Pulmonary Hypertension Due to Left Heart Disease by Aortic Debanding in Rats
07:41

A Model of Reverse Vascular Remodeling in Pulmonary Hypertension Due to Left Heart Disease by Aortic Debanding in Rats

Published on: March 1, 2022

2.9K
Right Ventricular Systolic Pressure Measurements in Combination with Harvest of Lung and Immune Tissue Samples in Mice
10:20

Right Ventricular Systolic Pressure Measurements in Combination with Harvest of Lung and Immune Tissue Samples in Mice

Published on: January 16, 2013

25.3K
Hemodynamic Characterization of Rodent Models of Pulmonary Arterial Hypertension
09:40

Hemodynamic Characterization of Rodent Models of Pulmonary Arterial Hypertension

Published on: April 11, 2016

21.0K

Área de la Ciencia:

  • Investigación cardiovascular
  • Biología molecular
  • Biología celular

Sus antecedentes:

  • La hipertensión arterial pulmonar (HAP) implica una presión arterial alta en los pulmones debido a cambios estructurales en las arterias pequeñas.
  • La HAP conduce a la insuficiencia del ventrículo derecho y es una causa significativa de mortalidad.
  • Los tratamientos actuales para la HAP ofrecen beneficios limitados a largo plazo, lo que requiere nuevos objetivos terapéuticos.

Objetivo del estudio:

  • Identificar nuevos objetivos moleculares para la hipertensión arterial pulmonar (HAP).
  • Investigar el papel de la quinasa de unión a la PDZ (PBK) en la patogénesis de la HAP.
  • Evaluar el potencial terapéutico de la focalización de PBK en modelos preclínicos de HAP.

Principales métodos:

  • Análisis de la expresión génica (microarray, secuenciación de ARN) en modelos de roedores y muestras humanas de HAP.
  • Estudios funcionales con enfoques de ganancia de función y pérdida de función para PBK.
  • Inhibición farmacológica de PBK y knockout genético (CRISPR/Cas9) en modelos de HAP.
  • Evaluación de la hipertensión pulmonar mediante ecografía, hemodinámica y morfometría.

Principales resultados:

  • La quinasa de unión a la PDZ (PBK) fue significativamente regulada al alza en las arterias pulmonares de múltiples modelos de HAP y pacientes humanos.
  • El PBK activo promovió la proliferación de células del músculo liso de la arteria pulmonar mediante la regulación de la citocinesis y la progresión del ciclo celular.
  • La inhibición farmacológica o la deleción genética de PBK atenuaron o previnieron el desarrollo de HAP y revirtieron la enfermedad establecida en modelos preclínicos.
  • Se encontró que el PBK interactúa con el regulador proteico de la citocinesis 1 (PRC1), un factor clave en la división celular.

Conclusiones:

  • La quinasa de unión a PDZ (PBK) es un mediador crítico de la remodelación y la proliferación de la arteria pulmonar en la HAP.
  • El papel de PBK en la regulación de la citoquinesis y la dinámica del ciclo celular lo convierte en un objetivo terapéutico prometedor para la HAP.
  • Dirigirse a PBK ofrece una estrategia potencial para revertir la remodelación vascular y mejorar los resultados en pacientes con hipertensión arterial pulmonar.